or Try an Advanced Search...

    Technical Analysis for CALT - Calliditas Therapeutics AB

    Grade Last Price % Change Price Change
    D 20.56 -0.38% -0.08
    CALT closed down 0.38 percent on Wednesday, May 8, 2024, on 35 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Up
    Historical CALT trend table...
    Date Alert Name Type % Chg
    Earnings Movers Other 0.00%
    Multiple of Ten Bullish Other 0.00%
    Inside Day Range Contraction 0.00%
    Overbought Stochastic Strength 0.00%
    Gapped Down Weakness 0.00%
    Stochastic Reached Overbought Strength -0.38%
    Earnings Movers Other -0.38%
    Multiple of Ten Bullish Other -0.38%
    Gapped Up Strength -0.38%
    Overbought Stochastic Strength -0.38%
    Older End-of-Day Signals for CALT ...

       Recent Intraday Alerts

    Alert Time
    Possible Inside Day about 9 hours ago
    10 DMA Support about 10 hours ago
    60 Minute Opening Range Breakout about 12 hours ago
    Gap Down Partially Closed about 13 hours ago
    Gapped Down (Partial) about 13 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    CALT Chart by TradingView
    Basic chart:

    Profile

    Calliditas Therapeutics AB Description

    Calliditas Therapeutics AB is a specialty pharmaceutical company based in Stockholm, Sweden. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which Calliditas can partially or completely participate in the commercialization efforts. Calliditas is focused on the development and commercialization of the product candidate Nefecon, a unique two step formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy (IgAN). Calliditas is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the United States.

    Classification
    Sector: Healthcare
    Industry: Drug Manufacturers - Specialty & Generic
    Keywords: Pharmaceutical Health Sciences Pharmacy Medication Pharmaceutical Products Kidney Disease Renal Disease Pharmaceutics

    Is CALT a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 6 Calliditas releases phase 2 results on head and neck cancer asset setanaxib
    May 6 Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib
    May 2 Xencor (XNCR) Moves 14.3% Higher: Will This Strength Last?
    Apr 29 Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Apr 24 Calliditas Therapeutics' 2023 Annual Report Published
    Apr 24 Calliditas Announces Positive NefIgArd Open Label Extension Results
    Apr 18 Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
    Apr 16 Novartis (NVS) Presents Positive Data on Rare Kidney Disease Drug
    Apr 9 Calliditas Therapeutics to Attend Conferences in April
    Apr 8 Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires
    See more CALT news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 29.3
    52 Week Low 15.25
    Average Volume 5,068
    200-Day Moving Average 19.67
    50-Day Moving Average 20.72
    20-Day Moving Average 19.20
    10-Day Moving Average 19.78
    Average True Range 1.24
    RSI (14) 54.13
    ADX 13.0
    +DI 17.52
    -DI 20.57
    Chandelier Exit (Long, 3 ATRs) 19.29
    Chandelier Exit (Short, 3 ATRs) 19.71
    Upper Bollinger Bands 21.01
    Lower Bollinger Band 17.38
    Percent B (%b) 0.88
    BandWidth 18.90
    MACD Line -0.11
    MACD Signal Line -0.39
    MACD Histogram 0.2834
    Fundamentals Value
    Market Cap 551.8 Million
    Num Shares 26.8 Million
    EPS -1.60
    Price-to-Earnings (P/E) Ratio -12.85
    Price-to-Sales 0.48
    Price-to-Book 17.01
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 21.76
    Resistance 3 (R3) 21.63 21.10 21.56
    Resistance 2 (R2) 21.10 20.79 21.16 21.50
    Resistance 1 (R1) 20.83 20.60 20.96 20.96 21.43
    Pivot Point 20.29 20.29 20.36 20.36 20.29
    Support 1 (S1) 20.03 19.99 20.16 20.16 19.69
    Support 2 (S2) 19.49 19.80 19.56 19.63
    Support 3 (S3) 19.23 19.49 19.56
    Support 4 (S4) 19.36